News | Linear Accelerators | January 04, 2021

RAD Technology Medical Systems to Expand their Patented Modular Building Portfolio

RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

January 4, 2021 — RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

In spite of the global pandemic, RAD has continued to grow and design new radiotherapy facility solutions that will allow hospitals and cancer centers to keep pace with the rapid advancements in radiation therapy equipment and employ the latest treatment techniques to improve outcomes for their patients.

RAD's newest radiotherapy offering will provide end users with three different building configuration options. Customers will be able to pick the configuration they want based on their programming needs and space availability. In addition, they will be able to quickly and easily add space to the facility if and as the need for more arises.

The basic configuration provides a radiotherapy treatment bunker and control room specifically designed to accommodate a low energy self-shielded linac. The second configuration includes gowning space, a restroom and a multipurpose space that can be used as an office, exam room or an alternate entry/waiting area. The final configuration builds upon the first two and provides an additional restroom, nurses' station, waiting & reception and more flex space for exam, office and/or physics/dosimetry.  This phased modular approach allows for a variety of configurations ranging from a temporary adjunctive radiotherapy bunker to a complete and permanent standalone radiotherapy treatment facility.

As with all of RAD's facilities, whether permanent or temporary, this new design will be built using off site construction methods leading to less construction taking place on site, minimizing the disruption for doctors, patients and staff.  It also takes advantage of RAD's patented granular shielding system. This unique construction method and shielding system allow the bunker to be assembled on site in a matter of days and treating patients in less than a month. By catering to this new breed of low energy, self-shielded equipment which is gaining a foothold in the radiotherapy market, RAD can offer a flexible array of options and deploy a functional and attractive facility with a small footprint at a variety of sites.

"We are excited to expand our portfolio with this new radiotherapy facility that will provide the perfect accommodation for the newest generation of linacs on the market," said Kenneth Wright, RAD's Vice President of Sales and Business Development.  "We are looking forward to 2021, and to deploying this new style of bunker and cancer center in Europe and the U.S."

For more information: www.radtechnology.com

Related Content

RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in...
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

News | Nuclear Imaging | December 22, 2020
December 22, 2020 — Researchers in the DO...
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
December 21, 2020 — According to recent studies, an increase in the...
Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according to updated 10-year data from the PRIME II study, presented at the 2020 San Antonio Breast Cancer Symposium

Getty Images

News | Radiation Therapy | December 15, 2020
December 15, 2020 — Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

News | PET Imaging | December 14, 2020
December 14, 2020 — Positron emission tomography (PET) imaging with...
Among patients with breast cancer treated with radiotherapy, under-recognition of symptoms was common in reports of pain, pruritus, edema and fatigue, with younger patients and Black patients having significantly increased odds of symptom under-recognition, according to data presented at the 2020 San Antonio Breast Cancer Symposium

Getty Images

News | Women's Health | December 14, 2020
December 14, 2020 — Among patients with breast cancer treated with radiotherapy, under-recognition of symptoms was co